Dr. John Cush RheumNow
2 years 10 months ago
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/3hb5Z7L9uw https://t.co/4gvSurl1nM
Dr. John Cush RheumNow
2 years 10 months ago
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/9PKvsEUTM3 https://t.co/gElp6tyEQZ
Dr. John Cush RheumNow
2 years 10 months ago
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/0XYeLLPDlK https://t.co/xN0PR1gj08
Dr. John Cush RheumNow
2 years 10 months ago
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/KtdQgTvw4o https://t.co/R70sj3oYPH
Dr. John Cush RheumNow
2 years 10 months ago
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0
Dr. John Cush RheumNow
2 years 10 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Dr. John Cush RheumNow
2 years 10 months ago
When #PMR Strikes Young, It Hits Hard
In this blogpost I want to talk about “young PMR”: when people develop PMR in what should be the prime of their lives. By this I mean people under 65, and even people under 50.
https://t.co/jHlppnddFf https://t.co/aB81hrYyHX
Dr. John Cush RheumNow
2 years 10 months ago
Controversies in #PMR
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
https://t.co/QLkypnPA2G https://t.co/y5EiLkB2yq
My colleague says, “I simply refer to physiotherapy. I don’t have time to discuss exercises, we need that time to discuss medications, side-effects, etc.” I sympathise. How do we promote activity and muscle strength among our patients?
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn
Dr. John Cush RheumNow
2 years 10 months ago
#PMR Mythbusters: PMR is Only Proximal
https://t.co/tRed7Zsaxi https://t.co/PWP5boH6NA
Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.
